Hypervirulent Klebsiella pneumoniae, a 5-year study in a French ICU.

CONCLUSION: hvKp represent a potentially underestimated cause of fatal infections in the Western world. PMID: 29972348 [PubMed - as supplied by publisher]
Source: Journal of Medical Microbiology - Category: Microbiology Authors: Tags: J Med Microbiol Source Type: research

Related Links:

This study aimed to detect patients ’ characteristics who suffered severe and critical COVID-19 pneumonia admitted to the post-acute COVID-19 rehabilitation clinic in Ankara City Hospital, Physical Medicine and Rehabilitation Hospital and to share our experiences and outcomes of rehabilitation programmes applied. This study was desi gned as a single-centre, retrospective, observational study. Severe and critical COVID-19 patients, admitted to the post-acute COVID-19 rehabilitation clinic, were included in patient-based rehabilitation programmes, targeting neuromuscular and respiratory recovery. Functional status, oxy...
Source: Rheumatology International - Category: Rheumatology Source Type: research
Source: International Journal of General Medicine - Category: General Medicine Tags: International Journal of General Medicine Source Type: research
Conditions:   Cutaneous Manifestations;   Skin Manifestations;   COVID-19;   COVID-19 Pneumonia;   COVID-19 Pandemic;   Corona Virus Infection;   Coronavirus Disease 2019;   Sars-CoV-2 Infection Intervention:   Sponsor:   Jinnah Postgraduate Medical Centre Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Noninvasive Ventilation;   Covid19;   Distress; Respiratory Syndrome, Adult Interventions:   Procedure: BiPAP;   Procedure: CPAP Sponsor:   Germans Trias i Pujol Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   COVID-19 Pneumonia Interventions:   Drug: Standart treatment group;   Drug: Montelukast sodium 10 mg treatment;   Drug: Montelukast sodium 20 mg treatment Sponsor:   Bugra Kerget Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Subarachnoid Hemorrhage;   Pneumonia, Bacterial Intervention:   Sponsor:   University Hospital, Brest Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Q fever is a common zoonosis with almost a worldwide distribution caused by Coxiella burnetii. Farm animals and pets are the main reservoirs of infection and transmission to humans is usually via inhalation of contaminated aerosols. Infection in humans is often asymptomatic, but it can manifest as an acute disease (usually a self-limited flu-like illness, pneumonia or hepatitis) or as a chro...
Source: African Journal of Microbiology Research - Category: Microbiology Source Type: research
AbstractThe first cluster of cases of COVID-19 pneumonia was reported on December 31, 2019. Since then, this disease has spread rapidly across the world, and as of September 17, 2021, there are 226,844,344 cases of COVID-19 worldwide with 4,666,334 deaths related to COVID-19. While most COVID-19 cases are mild, some cases are severe with patients developing acute respiratory distress syndrome (ARDS). The pathophysiology of ARDS includes damage to the alveolar epithelium that leads to increased permeability of the alveolar epithelial barrier causing hyaline membrane formation, interstitial edema, and alveolar edema that res...
Source: Emergency Radiology - Category: Emergency Medicine Source Type: research
Condition:   COVID-19 Pneumonia Intervention:   Diagnostic Test: Nasopharyngeal swap for RT-PCR Sponsor:   Sohag University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
More News: France Health | Genetics | Intensive Care | Liver | Microbiology | Pneumonia | Study | Urology & Nephrology